https://www.selleckchem.com/pr....oducts/ddr1-in-1.htm
erforming a dual role. Antiarrhythmic drug (AAD) therapy for atrial fibrillation (AF) can be associated with both proarrhythmic and noncardiovascular toxicities. Practice guidelines recommend tailored AAD therapy for AF based on patient-specific characteristics, such as coronary artery disease and heart failure, to minimize adverse events. However, current prescription patterns for specific AADs and the degree to which these guidelines are followed in practice are unknown. Patients enrolled in the Get With The Guidelines-Atrial Fibril
Like
Comment
Share
